Background Lowering of blood pressure prevents stroke but optimum target levels to prevent recurrent stroke are unknown. We investigated the eff ects of diff erent blood-pressure targets on the rate of recurrent stroke in patients with recent lacunar stroke. Findings 3020 enrolled patients, 1519 in the higher-target group and 1501 in the lower-target group, were followed up for a mean of 3·7 (SD 2·0) years. Mean age was 63 (SD 11) years. After 1 year, mean systolic blood pressure was 138 mm Hg (95% CI 137-139) in the higher-target group and 127 mm Hg (95% CI 126-128) in the lower-target group. Non-signifi cant rate reductions were seen for all stroke (hazard ratio 0·81, 95% CI 0·64-1·03, p=0·08), disabling or fatal stroke (0·81, 0·53-1·23, p=0·32), and the composite outcome of myocardial infarction or vascular death (0·84, 0·68-1·04, p=0·32) with the lower target. The rate of intracerebral haemorrhage was reduced signifi cantly (0·37, 0·15-0·95, p=0·03). Treatment-related serious adverse events were infrequent.
Introduction
Hypertension is the most relevant and prevalent risk factor for stroke, particularly for stroke associated with cerebral small-vessel disease. Reduction in blood pressure is the most eff ective intervention to prevent stroke. [1] [2] [3] Small subcortical brain infarcts, commonly known as lacunar strokes, comprise about 25% of ischaemic strokes. 4, 5 Most result from disease of the small penetrating arteries. Despite the frequency and importance of these strokes, randomised trials have not focused on prevention of recurrent stroke in patients with MRI-defi ned lacunar stroke. Whether there are optimum blood-pressure targets to prevent stroke recurrence in patients with cerebral small-artery disease is unknown. 6 In the Secondary Prevention of Small Subcortical Strokes (SPS3) trial we tested two interventions in patients with recent, symptomatic, MRI-confi rmed lacunar stroke: two antiplatelet regimens and two target ranges of systolic blood pressure. The results of the antiplatelet component have been published previously. 7 We present here the results of the blood-pressure component of the trial, in which we tested the hypothesis that assignment to a lower target range for systolic blood pressure would lessen the rate of stroke recurrence compared with a higher target range.
Methods

Patients
Details of the rationale, study design, and characteristics of the participants in SPS3 have been described elsewhere. 8, 9 Briefl y, SPS3 was a randomised, multicentre, clinical trial undertaken in 81 centres in North America, Latin America, and Spain between March, 2003, and April, 2011 . Eligible patients were aged 30 years or older, were normotensive or hypertensive, had had a recent (within 180 days), symptomatic, MRI-confi rmed lacunar stroke, and were without surgically amenable ipsilateral carotid artery stenosis or high-risk cardioembolic sources. Main exclusion criteria included disabling stroke (modifi ed Rankin score of 4 or higher), previous intracranial haemorrhage from non-traumatic causes, or cortical ischaemic stroke. 7, 8 Participation required written informed consent and approval was provided by local ethics committees for human research.
Randomisation and masking
Patients were randomised, according to a two-by-two factorial design, to two blood-pressure-control groups with targets of 130-149 mm Hg or less than 130 mm Hg. 10 Treatment was open label. To avoid lowering of blood pressure soon after an acute stroke, participants were randomised at least 2 weeks after the index stroke.
Randomisation was stratifi ed by clinical centre and baseline hypertensive status. The schedule was computer generated with a permuted-block design (variable block size). Treatment assignments were stored electronically on the study servers at the SPS3 statistical centre, University of Alabama at Birmingham, AL, USA, as well as locally for each study site on an SPS3-designated computer. Upon patients' eligibility being established, study coordinators ransomised patients via their data entry systems.
Management of blood pressure
Baseline hypertensive status was determined by measurement of blood pressure taken at two consecutive visits before randomisation. Patients taking medications to control blood pressure were allowed to continue doing so. Blood pressure was measured three times at every visit and the average measurement was used to decide hypertensive status. 8−11 Patients were classifi ed as being hypertensive if either or both of the following features were noted: average systolic blood pressure 140 mm Hg or higher or diastolic blood pressure 90 mm Hg or higher on two consecutive visits, and confi rmed history of hypertension before the index stroke and taking antihypertensive medication at the time of visit. After randomisation, if patients had blood pressures outside the assigned target range, they were initially seen at least monthly for measurement of blood pressure and adjustment of medications. Patients whose blood pressure was in the relevant range for two consecutive visits were seen every 3 months. If at any point during the study a patient's systolic blood pressure was outside the assigned target range, he or she was asked to return within 1 month.
All study sites were provided with automated Colin Press-Mate BP-8800C sphygmomanometers (Colin Medical Instruments, San Antonio, TX, USA).
11 Bloodpressure management was overseen at each site by a physician with special expertise in blood-pressure control. If systolic blood pressure in patients assigned to the higher-target group (130-149 mm Hg) dropped to below the lower limit of the target range, the protocol required that patients taking antihypertensive medications stop taking them or have the doses reduced, unless prescribed for reasons other than blood pressure control; patients taking no antihypertensive medications continued to be followed up every 3 months. If systolic blood pressure increased to within the target range, patients were managed according to their originally assigned target. If patients or primary-care physicians refused to titrate blood pressure to the assigned target range per protocol, patients were classifi ed as inactive. Patients whose blood pressure could not be kept within the assigned target range for medical reasons or because of intolerable side-eff ects of antihypertensive drugs after trying diff erent agents were classifi ed as failure to achieve assigned target. All participants were followed up to a common end-of-study date, irrespective of activity status.
Antihypertensive medications were prescribed by the local study physician and supplied via the study formularies. At least one drug from each of the major classes of Data are mean (SD) or number (%). TIA=transient ischaemic attack. ACE=angiotensin-converting enzyme. ARB=antiotensin-II-receptor blocker.*Diff erence between groups p<0·0001. †Diff erence between groups p<0·0001 for all types, except β blockers (p=0·0008) and other (p=0·051). ‡Diff erence between groups p<0·0001. §Diff erence between groups p<0·0001 for all types, except other (p=0·042). 
Statistical analysis
The primary endpoint was reduction in all stroke. Ischaemic stroke was clinically defi ned as a focal neurological defi cit persisting for longer than 24 h, with an absence of haemorrhage confi rmed by neuroimaging. Intracranial haemorrhages included intracerebral, subdural or epidural, and subarachnoid locations defi ned by neuroimaging. Disabling strokes were classi fi ed as those with modifi ed Rankin scores of 3 or higher after 3-6 months. Strokes were deemed fatal if death occurred within 30 days or if death after 30 days could be attributed to the stroke. Secondary endpoints were reductions in acute myocardial infarction, defi ned by standard criteria (compatible clinical history with changes on ECG or in cardiac enzyme concentrations), need for acute admission to hospital for a major vascular event, and death, classifi ed as vascular, non-vascular, or unknown. All reported effi cacy outcomes were con fi rmed by a central adjudication committee that was unaware of treatment assignment. Safety outcomes were serious adverse events related to hypotension and blood-pressure management. The trial was monitored by an independent data and safety monitoring committee selected by the sponsor.
The initial sample size of 2500 patients was calculated assuming an average follow-up of 3 years, an estimated 3-year recurrent stroke rate of 21%, a 25% relative-risk reduction in stroke by intensive control of blood pressure, a type I error of α=0·05, and 90% power. Sample-size estimation was reassessed midway through the trial to check the power of the study on the basis of the observed overall event rate. This assessment resulted in the fi nal sample size being increased from 2500 to 3000 patients. 12 We did two prespecifi ed subgroup analyses. The fi rst was in patients who were hypertensive at baseline. Thus, we excluded from this analysis patients who were nonhypertensive at baseline (systolic blood pressure lower than 130 mm Hg without taking antihypertensive medications) and who received no antihypertensive therapy during the study unless blood pressure exceeded the assigned target range during follow-up. The second included data after censoring at 6 months of follow-up. This analysis was undertaken because the maximum separation of the baseline and achieved blood pressures requires an average of 6 months of medication titration. All participants who did not die or withdraw from the study during the fi rst 6 months, irrespective of whether or not they had an event during this time, were included in this subgroup. We also assessed outcomes in various demographic and clinical subgroups.
We did standard time-to-event analyses of the primary endpoint with the log-rank test and used Cox's proportional hazards models to compute hazard ratios (HRs) and 95% CIs in each treatment group. If multiple events of the same type occurred, time to event was calculated as time to fi rst event. Data for patients with no events were censored at the end of study participation or death, whichever occurred fi rst. The proportional hazards assumption was verifi ed by assessment of the interaction between time and blood-pressure-intervention group, and we used Cox's models to investigate whether the eff ect of intervention diff ered by specifi c subgroups. Odds ratios and 95% CIs were computed by logistic regression for orthostatic symptoms, as these were measured as whether or not the patient had at least one symptom during the follow-up period All analyses were based on the intention-to-treat principle and were done with SAS (version 9.2). The study is registered with ClinicalTrials.gov, number NCT00059306.
Role of the funding source
The sponsor of the study participated in study design, data collection, data analysis, data interpretation, and writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
participants were enrolled from North America (n=1960 [65%]), Latin America (n=694 [23%])
, and Spain (n=366 [12%]) and were followed up for a mean of 3·7 (range 0-8·6, SD 2·0) years (appendix p 1). Baseline characteristics did not diff er substantially between target groups (table 1). The median time from qualifying stroke to randomisation was 62 days. Blood-pressure therapy was permanently discontinued in similar numbers of 
Number of events (annualised rate [%])
130-149 mm Hg
Subgroup (p interaction ) HR (95% CI)
<130 mm Hg
Age (p=0·53)
<65 years (n=1757) ≥65 years (n=1263)
Sex (p=0·50)
Male (n=1902) Female (n=1118)
History of diabetes (p=0·64)
Non-diabetic (n=1914) Diabetes (n=1106)
Race (p=0·85)
Hispanic (n=916) White (n=1538) Black (n=492) Other/mixed (n=74)
Region of residence (p=0·09)
North America (n=1960)
Latin America (n=694) Spain (n=366)
Baseline SBP (p=0·78)
Normotensive (n=314) SBP<median (n=1306) SBP≥median ( . 90 (3%) participants were lost to follow-up and an additional 465 (15%) ended follow-up early for the following reasons: withdrawn consent (n=242), site closure (n=151), physician request (n=12), and other reasons (n=60). At 1 year of follow up, the achieved average systolic blood pressures were 138 mm Hg (95% CI 137-139) in the higher-target group and 127 mm Hg (126-128) in the lower-target group, with 1139 (75%) and 976 (65%), respectively, having blood pressures within the assigned target ranges. At the last study visit, the mean diff erence in systolic blood pressures between the two groups was 11 mm Hg (SD 16, fi gure 1, appendix p 2). At 1 year, patients in the lower-target group had received a greater mean number of antihypertensive drugs than had those in the higher-target group (table 1) .
During follow-up, 277 fi rst recurrent strokes occurred. Of these, 243 (86%) were ischaemic (of which 173 [71%] were recurrent lacunar strokes) and 34 (14%) were intracranial haemorrhages. The annualised rate of recurrent stroke among those assigned to the highertarget group was 2·77%, as compared with 2·25% in the lower-target group (hazard ratio 0·81, 95% CI 0·64-1·03; p=0·08; table 2, fi gure 2). A similar result was seen for disabling or fatal stroke (table 2). The rate of intracerebral haemorrhage was signifi cantly reduced in the lower-target group, whereas mortality was nearly identical (table 2) . A 13% reduction in the rate of recurrent lacunar strokes was seen in the lower-target group (HR 0·87, 95% CI 0·62-1·22, p=0·41). There was no heterogeneity in treatment eff ect on the primary outcome in any of the demographic or clinical subgroups (fi gure 3).
In the prespecifi ed subgroup analysis restricted to the 2706 participants classifi ed as hypertensive at study entry, a 20% reduction in recurrent stroke was seen in the lowertarget group (appendix p 3). Censoring of the fi rst 6 months of follow-up in all participants showed a nearly identical rate reduction for recurrent stroke (appendix p 3).
Although few serious adverse events related to hypotension were noted, they were more frequent in the lowertarget group than in the higher-target group, but not signifi cantly so (table 3) . Syncope was the most frequent event but did not result in permanent sequelae. Symptoms potentially related to blood-pressure management were similar in the two groups (table 4).
Discussion
Lowering of systolic blood pressure to a target of less than 130 mm Hg in patients with recent lacunar stroke resulted in non-signifi cant reductions in all stroke, disabling or fatal stroke, and major vascular events, and a signifi cant reduction in intracerebral stroke. These eff ects were associated with few serious side-eff ects, and were consistent across major subgroups, including patients with diabetes and Hispanic patients, and irrespective of blood pressure at study entry. Exclusion of normotensive patients at entry showed a reduction in the rate of recurrent stroke of 20% in the lower-target group, although this reduction was not signifi cant. Bloodpressure lowering off ered a similar eff ect on stroke recurrence irrespective of stroke subtype (table 5, fi gure 4).
That lower is better is a general construct for chronic blood-pressure management after stroke, but optimum clinical practice requires that benefi ts and risks associated with specifi c targets be defi ned. The PROGRESS trial 2 showed that lowering of blood pressure in stroke survivors was associated with a reduction of 28% in stroke recurrence. The mean achieved systolic blood pressure at the end of the study was 138 mm Hg, but the optimum target for blood-pressure control was not established. Similarly to the ACCORD trial, 19 we explored the effi cacy and safety of setting systolic-blood-pressure targets lower than 130 mm Hg, but our assessment was extended to patients with MRI-defi ned lacunar stroke attributed to small-vessel disease.
Our results are best viewed in the context of previous trials of long-term lowering of blood pressure in patients who have had brain ischaemia (table 5, fi gure 4). [1] [2] [3] [13] [14] [15] [16] [17] 20 We tested target blood pressure rather than specifi c antihypertensive agents and explored eff ects in patients with well defi ned ischaemic-stroke subtypes. Although the magnitude of the reduction in rate was not signifi cant, the fi ndings are strongly supported by those of previous trials. The trial protocol was based on the assigned target of systolic blood pressure being achieved and, therefore, we did not require specifi c antihypertensive agents to be used. Patients assigned to the lower-target group used an average of 2·4 antihypertensive medications and the distribution of medication categories diff ered from that in the higher-target group (table 1). The mean diff erence in systolic blood pressure at the end of the trial was 11 mm Hg. On the basis of previous studies, this diff erence should have resulted in about a 30% reduction in recurrent stroke. The observed reduction of 19% (95% CI -3 to 36), however, was smaller even than the hypothesised 25%. This fi nding could be due to chance or the specifi c population of patients assessed. 2, 21 The 95% CI for the 19% reduction does include the hypothesised 25% reduction, but it also spans zero and, therefore, is not signifi cant. The rate of intracerebral haemorrhage was reduced by 63% in the lower-target group, which is consistent with the known sensitivity of this stroke subtype to strict blood-pressure control.
14 This result indicates that the number needed to treat to prevent one intracerebral haemorrhage at 4 years (roughly the average follow-up in SPS3) would be 175.
The SPS3 trial had limitations. First, the observed rate of recurrent stroke was much lower than that anticipated. This low rate is similar to that seen in other trials that have assessed prevention of recurrent stroke. [22] [23] [24] It might, therefore, be the result of good blood-pressure control in both treatment groups, the frequent use of statins, and high adherence to antiplatelet therapy. Second, the assign ment to bloodpressure targets was not masked, which could have potentially introduced bias. Stroke end points were, however, confi rmed by a central adjudication committee that was unaware of patients' group allo cations, as is frequently done in large hyper tension trials. 25 Third, we tested treatment targets and not the eff ect of specifi c blood-pressure agents. Finally, some patients did not achieve blood pressures within the target ranges at any point during follow-up (70 [4·6%] in the higher-target group and 74 [4·9%] in the lower-target group). These proportions, however, are similar to those reported in other trials of blood-pressure targets and, therefore, probably refl ect the clinical realities of blood-pressure management. 19, 25 An important strength of the SPS3 Relative-risk reduction (95% CI) for recurrent stroke (%) Figure 4 : Randomised trials of long-term blood-pressure lowering for secondary stroke prevention trial is that blood-pressure lowering was tested in a well defi ned and homogeneous cohort of stroke patients.
In conclusion, although our results do not show a signifi cant reduction in the rate of recurrent stroke, the fi ndings are congruent with those of previous trials of blood-pressure lowering after stroke and support a treatment target of less than 130 mm Hg systolic blood pressure for most patients with recent lacunar stroke (panel). As our study cohort comprised patients with recent lacunar strokes due mainly to cerebral smallvessel disease, whether our fi ndings are applicable to patients with strokes from other mechanisms warrants additional research.
